Progesterone receptor and PTEN expression predict survival in patients with low-and intermediate-grade pancreatic neuroendocrine tumors

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 8, 2014, Pages 1027-1036

  Estrella, Jeannelyn S ^a   Broaddus, Russell R ^a   Mathews, Amber ^a   Milton, Denái R ^a   Yao, James C ^a   Wang, Huamin ^a   Rashid, Asif ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PTEN PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CANCER CENTER; CANCER GRADING; CANCER STAGING; DOWN REGULATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; UNITED STATES;

BIOLOGICAL MARKERS; CANCER CARE FACILITIES; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TEXAS;

EID: 84907267768     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0195-OA     Document Type: Article

References (40)

1. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010. World Health Organization Classification of Tumours; vol 3.
2. Martin RC, Kooby DA, Weber SM, et al. Analysis of 6, 747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg. 2011; 15(1): 175-183.
3. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14(23): 7798-7803.
4. Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncology. 2007;25(35): 5609-5615.
5. Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95(5): 627-635.
6. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20(11): 2633-2642.
7. Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40(1): 30-40.
8. Edge SB; American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
9. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35(6): 853-860.
10. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28(2): 245-255.
11. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331(6021): 1199-1203.
12. Ghayouri M, Boulware D, Nasir A, Strosberg J, Kvols L, Coppola D. Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res. 2010;30(12): 5063-5067.
13. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6): 514-523.
14. Meric-Bernstam F, Akcakanat A, Chen H, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012;18(6): 1777-1789.
15. Corbo V, Beghelli S, Bersani S, et al. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol. 2012;23(1): 127-134.
16. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7): 1261-1274.
17. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3): 403-414.
18. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5): 283-296.
19. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 2007;28(7): 1379-1386.
20. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res. 2010;16(17): 4325-4330.
21. Arnason T, Sapp HL, Barnes PJ, Drewniak M, Abdolell M, Rayson D. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Neuroendocrinology. 2011;93(4): 249-258.
22. Viale G, Doglioni C, Gambacorta M, Zamboni G, Coggi G, Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors: an immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992;70(9): 2268-2277.
23. Alabraba EB, Taniere P, Reynolds GM, Stewart PM, Wigmore SJ, Bramhall SR. Expression and functional consequences of oestrogen and progesterone receptors in human insulinomas. Endocr Relat Cancer. 2007;14(4): 1081-1088.
24. Wang Y, He X, Ngeow J, Eng C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgenindependent suppression of PTEN transcription in breast cancer. Hum Mol Genet. 2012;21(3): 569-576.
25. Kamalakaran S, Radhakrishnan SK, Beck WT. Identification of estrogenresponsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites. J Biol Chem. 2005;280(22): 21491-21497.
26. Yang L, Wang Y, Chen P, et al. Na(+)/H(+) exchanger regulatory factor 1 (NHERF1) is required for the estradiol-dependent increase of phosphatase and tensin homolog (PTEN) protein expression. Endocrinology. 2011;152(12): 4537-4549.
27. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 2003;17(4): 575-588.
28. Gu C, Zhang Z, Yu Y, et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci. 2011;102(3): 557-564.
29. Hammond ME, Hayes DF, Wolff AC. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29(15): e458.
30. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5): 1474-1481.
31. Sangale Z, Prass C, Carlson A, et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol. 2011;19(2): 173-183.
32. Perren A, Komminoth P, Saremaslani P, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 2000;157(4): 1097-1103.
33. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011; 11(4): 289-301.
34. Escriva M, Peiro S, Herranz N, et al. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol. 2008;28(5): 1528-1540.
35. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2): 647-658.
36. Djordjevic B, Hennessy BT, Li J, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012;25(5): 699-708.
37. Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol. 2012;31(1): 48-56.
38. Krausch M, Raffel A, Anlauf M, et al. Loss of PTEN expression in neuroendocrine pancreatic tumors. Horm Metab Res. 2011;43(12): 865-871.
39. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996;27(11): 1124-1134.
40. Tokunaga E, Oki E, Kimura Y, et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat. 2007;101(3): 249-257.